These findings demonstrate that the increased rate of AB12 tumor growth resulting from pretreatment with sTGF-βR is not due to an effect on the migration or activation (assessed by expression levels of CD86 and MHC class I and II) of DCs. The gene discussed is HLA-C; the disease is neoplasm.